AIM OF THE STUDY: Rhizoma coptidis is used widely in traditional Oriental medicine to treat inflammatory diseases. The aim of this study was to identify the anti-inflammatory target genes of Rhizoma coptidis extract (CEX) in lipopolysaccharide (LPS)-stimulated RAW264.7 murine macrophage-like cells. MATERIALS AND METHODS: RAW264.7 cells were treated with CEX in the absence or presence of LPS for 6h, and changes in gene expression profiles were analyzed using oligonucleotide DNA microarrays. The results of microarray analysis were validated by semiquantitative reverse transcription-polymerase chain reaction. To confirm the anti-inflammatory activity of CEX, the concentrations of cytokines released into the media were measured by sandwich ELISA, NO production was assessed using the Griess reagent, and iNOS expression levels were determined using immunoblot analysis. RESULTS: Microarray analysis revealed that activation of RAW264.7 cells with LPS elicited marked changes in mRNA expression of numerous genes known to be associated with inflammatory responses. Treatment of the cells with CEX suppressed the expression of various cytokines/chemokines, cell surface molecules, adhesion molecules, and growth factors. An ELISA also showed a decrease in the secretion of IL-1alpha, GM-CSF, and IL-6 but not of TNF-alpha. iNOS protein expression and NO production were also reduced by CEX treatment. CONCLUSIONS: The data obtained in this study demonstrate that CEX exerts its anti-inflammatory effect by inhibiting the expression of various proinflammatory cytokines and cell surface molecules involved in inflammatory responses at the transcriptional level. These data support the traditional use of CEX as an anti-inflammatory agent and should provide useful information for the understanding of the pharmacological effects of CEX. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
AIM OF THE STUDY: Rhizoma coptidis is used widely in traditional Oriental medicine to treat inflammatory diseases. The aim of this study was to identify the anti-inflammatory target genes of Rhizoma coptidis extract (CEX) in lipopolysaccharide (LPS)-stimulated RAW264.7 murine macrophage-like cells. MATERIALS AND METHODS: RAW264.7 cells were treated with CEX in the absence or presence of LPS for 6h, and changes in gene expression profiles were analyzed using oligonucleotide DNA microarrays. The results of microarray analysis were validated by semiquantitative reverse transcription-polymerase chain reaction. To confirm the anti-inflammatory activity of CEX, the concentrations of cytokines released into the media were measured by sandwich ELISA, NO production was assessed using the Griess reagent, and iNOS expression levels were determined using immunoblot analysis. RESULTS: Microarray analysis revealed that activation of RAW264.7 cells with LPS elicited marked changes in mRNA expression of numerous genes known to be associated with inflammatory responses. Treatment of the cells with CEX suppressed the expression of various cytokines/chemokines, cell surface molecules, adhesion molecules, and growth factors. An ELISA also showed a decrease in the secretion of IL-1alpha, GM-CSF, and IL-6 but not of TNF-alpha. iNOS protein expression and NO production were also reduced by CEX treatment. CONCLUSIONS: The data obtained in this study demonstrate that CEX exerts its anti-inflammatory effect by inhibiting the expression of various proinflammatory cytokines and cell surface molecules involved in inflammatory responses at the transcriptional level. These data support the traditional use of CEX as an anti-inflammatory agent and should provide useful information for the understanding of the pharmacological effects of CEX. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
Authors: Yungwui Tjong; Siupo Ip; Lixing Lao; Harry H S Fong; Joseph J Y Sung; Brian Berman; Chuntao Che Journal: J Ethnopharmacol Date: 2011-04-12 Impact factor: 4.360
Authors: Kook Ho Sohn; Mi Jeong Jo; Won Joon Cho; Jong Rok Lee; Il Je Cho; Sang Chan Kim; Young Woo Kim; Seon Young Jee Journal: Evid Based Complement Alternat Med Date: 2012-10-08 Impact factor: 2.629
Authors: Jing-Fei Jiang; Yu-Gang Wang; Jun Hu; Fan Lei; Michael M Kheir; Xin-Pei Wang; Yu-Shuang Chai; Zhi-Yi Yuan; Xi Lu; Dong-Ming Xing; Feng Du; Li-Jun Du Journal: PLoS One Date: 2013-01-15 Impact factor: 3.240
Authors: Gesa Meyer-Hamme; Kathrin Beckmann; Janine Radtke; Thomas Efferth; Henry Johannes Greten; Matthias Rostock; Sven Schröder Journal: Evid Based Complement Alternat Med Date: 2013-10-28 Impact factor: 2.629